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resBACKGROUND Atrial ﬁbrillation (AF) is common in heart failure (HF), but the outcome by type of AF is largely
unknown.
OBJECTIVES This study investigated outcomes related to type of AF (paroxysmal, persistent or permanent, or new
onset) in 2 recent large trials in patients with HF with reduced ejection fraction.
METHODS The study analyzed patients in the PARADIGM-HF (Prospective comparison of ARNI with ACEI to Determine
Impact on Global Mortality and morbidity in Heart Failure) and ATMOSPHERE (Aliskiren Trial to Minimize Outcomes
in Patients with Heart Failure) trials. Multivariable Cox regression models were used to estimate hazard ratios (HRs) for
outcomes related to AF type.
RESULTS Of 15,415 patients, 5,481 (35.6%) had a history of AF at randomization, and of these, 1,645 (30.0%) had
paroxysmal AF. Compared with patients without AF, patients with paroxysmal AF at randomization had a higher risk of
the primary composite endpoint of cardiovascular death or HF hospitalization (HR: 1.20; 95% conﬁdence interval [CI]:
1.09 to 1.32; p < 0.001), HF hospitalization (HR: 1.34; 95% CI: 1.19 to 1.51; p < 0.001), and stroke (HR: 1.34; 95% CI: 1.02
to 1.76; p ¼ 0.037), whereas the corresponding risks in patients with persistent or permanent AF were not elevated.
Neither type of AF was associated with higher mortality. New onset AF was associated with the greatest risk of adverse
outcomes: primary endpoint (HR: 2.21; 95% CI: 1.80 to 2.71), HF hospitalization (HR: 2.11; 95% CI: 1.58 to 2.81),
stroke (HR: 2.20; 95% CI: 1.25 to 3.88), and all-cause mortality (HR: 2.26; 95% CI: 1.86 to 2.74), all p values < 0.001,
compared with patients without AF. Anticoagulants were used less often in patients with paroxysmal (53%) and new
onset (16%) AF than in patients with persistent or permanent AF (71%).
CONCLUSIONS Among HF patients with a history of AF, those with paroxysmal AF were at greater risk of HF
hospitalization and stroke than were patients with persistent or permanent AF, underlining the importance of anticoagulant
therapy. New onset AF was associated with increased risk of all outcomes. (Prospective comparison of ARNI with ACEI
to Determine Impact on Global Mortality and Morbidity in Heart Failure [PARADIGM-HF]; NCT01035255) (Aliskiren Trial to
Minimize Outcomes in Patients with Heart Failure [ATMOSPHERE]; NCT00853658) (J Am Coll Cardiol 2017;70:2490–500)
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AB BR E V I A T I O N S
AND ACRONYM S
AF = atrial ﬁbrillation
CI = conﬁdence interval
ECG = electrocardiogram
eGFR = estimated glomerular
ﬁltration rate
HF = heart failure
HFrEF = heart failure with
reduced ejection fraction
HR = hazard ratio
LVEF = left ventricular
ejection fraction
NT-proBNP = N-terminal
pro–B-type natriuretic peptide
NYHA = New York Heart
Association
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2491A trial ﬁbrillation (AF) is the most commonarrhythmia in patients with heart failurewith reduced ejection fraction (HFrEF),
with a prevalence that increases with severity of
heart failure (HF), reaching up to 50% in patients
in New York Heart Association (NYHA) functional
class IV (1,2). In some studies, AF has been associ-
ated with a poorer prognosis in HFrEF but this has
not been a consistent ﬁnding after adjustment for
other variables associated with worse outcomes. As
a result, there is controversy about whether AF is
an independent prognostic factor in HFrEF (3–5).
The different ﬁndings reported may reﬂect the
completeness of clinical data available for adjust-
ment, including information related to medical his-
tory, comorbidity, and physiological and laboratory
measurements. Notably, no study in chronic HFrEF
included measurement of natriuretic peptides, the
most powerful independent predictor of outcome
in this condition. AF was also inconsistently deﬁned
in existing studies with some using medical history
and others using the baseline electrocardiogram
(ECG) to identify AF (4,6). Consequently, existing
analyses have not examined whether type of AF
(paroxysmal vs. persistent or permanent) is related
to outcome. Similarly, the relationship between
incident AF and outcomes has rarely been examined
in previous studies.SEE PAGE 2501To address these outstanding questions, we have
examined the association between AF and outcomes
in the PARADIGM-HF (Prospective comparison of
ARNI with ACEI to Determine Impact on Global Mor-
tality and Morbidity in Heart Failure) and ATMO-
SPHERE (Aliskiren Trial to Minimize Outcomes in
Patients with Heart Failure) trials, the 2 most recent
and largest global multicenter randomized trials in
patients with HFrEF (7,8). The trials had an almost
identical design and detailed clinical data, including
history of AF, were collected at baseline. B-type
natriuretic peptides were measured, and an ECG wasNovartis had no role in this analysis. Except for Dr.Mogensen, all authors or th
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Manuscript received September 6, 2017; accepted September 10, 2017.also recorded, at baseline, in all patients in
both trials. Cardiovascular events during
follow-up, including new onset AF, were
adjudicated by the same endpoint
committee.
The main aim of the present study was to
investigate the association between type of
AF at baseline (paroxysmal vs. persistent or
permanent) and outcomes in HFrEF, after
fully adjusting for other prognostic variables,
including natriuretic peptides. We also
examined the association between incident
AF during follow-up and outcomes.
METHODS
A complete list of the PARADIGM-HF trial and
ATMOSPHERE trial investigators and com-
mittees can be found in the Online Appendix.
STUDY POPULATION AND PROCEDURES. The study
design and main results of both PARADIGM-HF and
ATMOSPHERE trials have been published (7–11). The
inclusion and exclusion criteria of the 2 trials were
almost identical. Brieﬂy, patients were eligible at
screening if they were $18 years of age, had NYHA
functional class II to IV, had left ventricular ejection
fraction (LVEF) #35% (changed from #40% initially
in the PARADIGM-HF trial by amendment), had
elevated natriuretic peptides (cutoff level indepen-
dent of AF), and took an angiotensin-converting
enzyme inhibitor or angiotensin receptor blocker,
along with a beta-blocker (unless contraindicated
or not tolerated) and a mineralocorticoid receptor
antagonist, if indicated. Exclusion criteria at
screening included symptomatic hypotension or sys-
tolic blood pressure <95 mm Hg (<90 mm Hg in the
ATMOSPHERE trial), estimated glomerular ﬁltration
rate (eGFR) <30 ml/min/1.73 m2 (<35 ml/min/1.73 m2
in the ATMOSPHERE trial), and potassium
>5.4 mmol/l (>5.2 mmol/l in the ATMOSPHERE trial).
The trial was approved by ethics committees at all
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the ATMOSPHERE trial, and all patients provided
written informed consent.
On trial entry, ongoing therapy with an
angiotensin-converting enzyme inhibitor or angio-
tensin receptor blocker was stopped and patients
entered a sequential run-in, ﬁrst receiving enalapril
followed by sacubitril/valsartan in the PARADIGM-HF
trial and enalapril followed by the combination
of enalapril plus aliskiren in the ATMOSPHERE
trial. Patients tolerating both run-in periods were
randomly assigned to double-blind therapy with
sacubitril/valsartan or enalapril in a 1:1 ratio in the
PARADIGM-HF trial or enalapril, aliskiren, or both
drugs in a 1:1:1 ratio in the ATMOSPHERE trial.
Information on AF at the randomization visit was
based on themedical history (investigators were asked
to state whether there was a history of AF and if yes,
whether the AF was paroxysmal or persistent or
permanent) and analysis of the baseline ECG
(investigators were asked to report whether this
showed AF). The few patients with a history of atrial
ﬂutter or atrial ﬂutter on their baseline ECG were
classiﬁed as unspeciﬁed AF. In a sensitivity analysis,
AFwas deﬁned according to the presence or absence of
AF or atrial ﬂutter on the ECG at randomization alone.
Among patients without AF (no history of AF and
no AF in the ECG) at baseline, new onset AF was
identiﬁed as a clinical endpoint using a speciﬁc case
report form in both studies. The CHA2DS2-VASc
(congestive heart failure, hypertension, age $75
years; diabetes mellitus, prior stroke or transient
ischemic attack or thromboembolism, vascular dis-
ease, age 65–74 years, sex category) score, reﬂecting
the risk of thromboembolic events, was calculated
using patient characteristics at randomization. The
HAS-BLED score was similarly used to calculate
bleeding risk (with a point for alcohol consumption
given if patients reported >1 drinks/day).
OUTCOMES. The primary outcome of both trials was
a composite of cardiovascular death or HF hospitali-
zation. In the present study, we investigated the
association between AF and risk of the primary
outcome, each of its components, death due to
worsening HF, sudden death, all-cause mortality, and
stroke. All endpoints were adjudicated by the same
clinical endpoint committee according to pre-
speciﬁed criteria.
STATISTICAL ANALYSES. Baseline characteristics
are presented as mean  SD or median (interquartile
range) for continuous variables and frequency and
percentage for categorical variables. Differences in
baseline characteristics according to type of AF atbaseline were assessed using the chi-square test for
categorical variables and either 2-sided Student’s t-test
or the Kruskal-Wallis test for continuous variables.
Incidence rates for the outcomes of interest are
presented per 100 person-years. Cumulative inci-
dence functions for outcomes of interest with death
as a competing risk were compared according to AF
status at randomization. Gray’s test was used to
compare the cumulative incidence functions. Rela-
tive hazard ratios (HRs) with 95% conﬁdence in-
tervals (CIs) of outcomes according to type of AF were
calculated using cause-speciﬁc Cox proportional
hazard models using no AF as reference. To assess the
prognostic signiﬁcance of new onset AF during
follow-up, AF was included as a time-dependent
variable. Thereby, the patients who developed new
onset AF were removed from the no-AF subgroup and
instead classiﬁed as new onset AF from the date of
new onset AF and onward.
Final models included adjustment for randomized
treatment (enalapril, sacubitril/valsartan, aliskiren,
or combination of enalapril and aliskiren), and the
following baseline characteristics: age, sex, region,
race, NYHA functional class, LVEF, heart rate, systolic
blood pressure, eGFR, diabetes, body mass index,
time since HF diagnosis, history of HF hospitaliza-
tion, history of stroke, prior myocardial infarction,
and log N-terminal pro–B-type natriuretic peptide
(NT-proBNP).
Analyses were performed using Stata version 13
(StataCorp, College Station, Texas). Two-sided
p values < 0.05 were considered signiﬁcant.
RESULTS
BASELINE CHARACTERISTICS. Of the 15,415 patients
randomized in both trials, 5,481 (35.6%) patients had
a history of AF. Of these, 3,770 (68.8%) patients were
categorized as having persistent or permanent AF
and 1,645 (30.0%) patients were categorized as having
paroxysmal AF (66 patients had undeﬁned AF). A
total of 3,654 (23.7%) patients had AF on their base-
line ECG and 369 patients developed new onset AF
during follow-up.
PATIENTS WITH PERSISTENT OR PERMANENT VERSUS
PAROXYSMAL AF VERSUS PATIENTSWITHOUT AF. Base-
line patient characteristics according to AF status are
presented in Table 1. Patients with both types of AF
were older, more often men, had longer duration HF,
worse NYHA functional class and Kansas City Car-
diomyopathy Questionnaire score, lower eGFR, and
more often had a history of prior HF hospitalization,
hypertension, stroke, and chronic obstructive pul-
monary disease compared with patients without a
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types of AF compared with those without, as was
median NT-proBNP.
Patients with persistent or permanent AF less often
had an ischemic etiology (50.6%) than either patients
with paroxysmal AF (63.6%) or patients without AF
(60.2%) did. There was a similar difference in history
of myocardial infarction (30.0%, 49.2%, and 45.5% in
each group, respectively).
The frequency of use of a beta-blocker was similar
according to baseline AF status but the use of di-
uretics was more frequent in patients with either type
of AF compared with those without AF. The use of
digoxin was much more common in patients with
persistent or permanent AF (50.8%) than in those
with paroxysmal AF (28.7%) and in patients without
AF (23.8%). The pattern of use of amiodarone also
differed considerably (used in 8.7%, 24.9%, and 7.1%
of each group, respectively).
The average CHA2DS2-VASc score was lowest in pa-
tients without AF (3.5 1.7) but higher in patients with
paroxysmal AF (4.1  1.8) than in patients with
persistent or permanent AF (3.9 1.8; p¼ 0.005). More
than 90% of patients in each AF category had a
CHA2DS2-VASc score of 2 or more (Online Appendix,
Online Table 1, Online Figure 1). Oral anticoagulants
were used most commonly in patients with persistent
or permanent AF (71.2%), at an intermediate level in
thosewith paroxysmal AF (53.1%), and least frequently
in individuals with no history of AF (16.0%). The
opposite was true for antiplatelet therapy (used in
31.4%, 50.8%, and 67.8% of each group, respectively).
PATIENTS WITH NEW ONSET (INCIDENT) AF. Patients
with new onset (incident) AF had characteristics in-
termediate between those without AF and patients
with paroxysmal AF (Table 1). The more striking dif-
ferences were in duration of HF (longer than in those
without a history of AF) and NT-proBNP, which was
as high as in those with persistent or permanent AF.
Baseline pharmacological treatment was similar to
that in patients without a history of AF.
ASSOCIATION BETWEEN AF AND OUTCOMES. Incidence
rates and hazard ratios for the risk of each outcome of
interest, according to presence of AF at baseline or
during follow-up, are presented in Table 2, Figure 1,
and the Central Illustration.
PATIENTS WITH PAROXYSMAL VERSUS PERSISTENT
OR PERMANENT VERSUS NO AF. In unadjusted
analyses, rates of each of the primary composite
endpoints, cardiovascular death, HF hospitalization,
all-cause mortality, and stroke were higher in pa-
tients with both types of AF compared withindividuals without a history of AF (Table 2,
Figure 1). However, in adjusted analyses, the risk of
the primary endpoint was only higher in patients
with paroxysmal AF (HR: 1.20; 95% CI: 1.09 to 1.32;
p < 0.001), compared with patients without AF. This
was not the case for patients with persistent or
permanent AF (HR: 0.94; 95% CI: 0.87 to 1.02;
p ¼ 0.138). This higher risk of the primary composite
endpoint among patients with paroxysmal AF was
primarily due to a higher risk of HF hospitalization
(HR: 1.34; 95% CI: 1.19 to 1.51; p < 0.001) compared
with patients with no history of AF, and compared
with patients with persistent or permanent AF (HR:
1.42; 95% CI: 1.25 to 1.63; p < 0.001) rather than
cardiovascular death (HR: 1.09; 95% CI: 0.97 to 1.24;
p ¼ 0.156; HR: 1.12; 95% CI: 0.98 to 1.28; p ¼ 0.088,
respectively).
Patients with paroxysmal AF also had a higher risk
of stroke compared with patients with no AF (HR:
1.34; 95% CI: 1.02 to 1.76; p ¼ 0.037), although this
was not apparent when compared with patients with
persistent or permanent AF (HR: 1.04; 95% CI: 0.83 to
1.32; p ¼ 0.72) (Table 2, Central Illustration).
Finally, patients with paroxysmal AF had a higher
risk of pump-failure death when compared with
patients with no AF (HR: 1.53; 95% CI: 1.22 to 1.91;
p < 0.001) and when compared with patients with
persistent or permanent AF (HR: 1.35; 95% CI: 1.06 to
1.71; p ¼ 0.014). However, neither type of AF was
associated with higher overall mortality (Table 2,
Central Illustration).
Sens i t iv i ty ana lys i s : pat ients with AF on the i r
basel ine ECG. Patients with AF or atrial ﬂutter on
their baseline ECG (n ¼ 3,760) did not have an
elevated risk of the primary endpoint (adjusted HR:
0.91; 95% CI: 0.84 to 0.98; p ¼ 0.014), CV death
(adjusted HR: 0.94; 95% CI: 0.86 to 1.03; p ¼ 0.18), HF
hospitalization (adjusted HR: 0.90; 95% CI: 0.81 to
0.99; p ¼ 0.036), or all-cause mortality (adjusted HR:
0.92; 95% CI: 0.85 to 1.00; p ¼ 0.06), compared with
patients without AF on their baseline ECG.
Pat ients wi th inc ident (new onset) AF . Patients
who developed new onset AF during follow-up were
at higher risk of the primary endpoint, each of
its components, all-cause mortality, and stroke
compared with patients without AF at baseline and
during follow-up (Table 2, Central Illustration, Online
Appendix, Online Figure 2). Patients with new onset
AF also had a higher adjusted risk of the primary
endpoint compared with patients with a history of AF
at baseline: (HR: 2.13; 95% CI: 1.73 to 2.62), CV death
(HR: 2.37; 95% CI: 1.92 to 2.91), HF hospitalization
(HR: 1.91; 95% CI: 1.46 to 2.60), all-cause mortality
(HR: 2.24; 95% CI: 1.85 to 2.73), all p values <0.001,
TABLE 1 Baseline Characteristics by AF Type
AF Type at Randomization
No AF
(n ¼ 9,828)
Paroxysmal (I)
(n ¼ 1,645)
Persistent/Permanent (II)
(n ¼ 3,770)
p Value
(I vs. II)
New Onset AF
(n ¼ 369)
Age at screening, yrs 61.6  11.8 66.9  10.1* 67.2  10.3* 0.292 64.3  11.6*
Female 2,245 (22.8) 329 (20.0)† 755 (20.0)† 0.982 56 (15.2)†
Region <0.001
North America 478 (4.9) 178 (10.8)* 116 (3.1)* 29 (7.9)*
Latin America 1,910 (19.4) 143 (8.7)* 468 (12.4)* 47 (12.7)*
Western Europe 2,267 (23.1) 533 (32.4)* 1,055 (28.0)* 114 (30.9)*
Central Europe 2,357 (24.0) 581 (35.3)* 1,774 (47.1)* 112 (30.4)*
Asia/Paciﬁc and other 2,816 (28.7) 210 (12.8)* 357 (9.5)* 67 (18.2)*
Race <0.001
White 5,580 (56.8) 1,307 (79.5)* 3,133 (83.1)* 269 (72.9)*
Black 419 (4.3) 52 (3.2)* 59 (1.6)* 10 (2.7)*
Asian 2,726 (27.7) 194 (11.8)* 327 (8.7)* 61 (16.5)*
Other 1,103 (11.2) 92 (5.6)* 251 (6.7)* 29 (7.9)*
Systolic blood pressure, mm Hg 121.9  16.8 123.0  17.4† 123.5  16.3* 0.307 124.0  17.7†
Heart rate, beats/min 71.1  11.3 69.8  12.5* 75.4  13.6* <0.001 69.5  12.0†
eGFR, ml/min/1.73 m2 72.7  22.1 64.2  18.5* 67.7  23.0* <0.001 70.5  23.1†
Ischemic HF etiology 5,915 (60.2) 1,046 (63.6)† 1,907 (50.6)* <0.001 225 (61.0)
Ejection fraction, % 28.5  6.0 29.1  6.1* 30.3  5.6* <0.001 29.2  6.1†
BMI, kg/m2 27.2  5.4 28.4  5.3* 29.1  5.4* <0.001 28.5  5.2*
BMI category <0.001
<18.5 kg/m2 266 (2.7) 15 (0.9)* 23 (0.6)* 4 (1.1)*
18.5–24.9 kg/m2 3,293 (33.6) 435 (26.5)* 802 (21.3)* 79 (21.4)*
25–29.9 kg/m2 3,688 (37.6) 644 (39.2)* 1,460 (38.8)* 167 (45.3)*
$30 kg/m2 2,565 (26.1) 549 (33.4)* 1,475 (39.2)* 119 (32.2)*
NYHA functional class <0.001
I 446 (4.5) 42 (2.6)* 72 (1.9)* 14 (3.8)
II 7,207 (73.4) 1,133 (69.0)* 2,298 (61.0)* 260 (70.5)
III 2,108 (21.5) 455 (27.7)* 1,352 (35.9)* 91 (24.7)
IV 61 (0.6) 12 (0.7)* 44 (1.2)* 4 (1.1)
Duration of HF 0.861
#1 yr 3,517 (35.8) 399 (24.3) 925 (24.5)* 80 (21.7)*
1–5 yrs 3,675 (37.4) 624 (37.9)* 1,449 (38.4)* 144 (39.1)*
>5 yrs 2,632 (26.8) 622 (37.8)* 1,396 (37.0)* 144 (39.1)*
Current smoking 1,516 (15.4) 195 (11.9)† 377 (10.0)* 0.041 46 (12.5)
Continued on the next page
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2494and stroke (HR: 1.91; 95% CI: 1.08 to 3.38; p ¼ 0.026).
The median time from new onset AF to HF hospital-
ization in those experiencing this event was 131
(interquartile range [IQR]: 43 to 454) days.
Sensitivity analysis: reclassifying patients with persistent
AF but no AF in the baseline ECG. Among patients with
persistent AF, 543 (14.4%) did not have AF on the
baseline ECG. If these patients were reclassiﬁed
as patients with paroxysmal AF, paroxysmal AF
remained associated with an increased risk of HF
hospitalization compared with patients with no AF
(HR: 1.28; 95% CI: 1.15 to 1.43; p < 0.001), and
compared with patients with persistent or permanent
AF (HR: 1.42; 95% CI: 1.25 to 1.62; p < 0.001). How-
ever, the higher risk of stroke in patients with
paroxysmal AF versus those with no AF was no longerstatistically signiﬁcant (HR: 1.21; 95% CI: 0.94 to 1.57;
p ¼ 0.15). Associations between type of AF and out-
comes otherwise remained generally unchanged
(Online Table 2).
DISCUSSION
We investigated the association between AF and out-
comes in HFrEF. We found that, after adjustment for
other prognostic variables, including natriuretic pep-
tides, paroxysmal, but not persistent or permanent AF,
was associated with a higher risk of the composite
outcome of HF hospitalization or death from cardio-
vascular causes (Central Illustration). The higher risk
was primarily related to an elevated risk of hospital
admission for worsening HF. Paroxysmal AF was also
TABLE 1 Continued
AF Type at Randomization
No AF
(n ¼ 9,828)
Paroxysmal (I)
(n ¼ 1,645)
Persistent/Permanent (II)
(n ¼ 3,770)
p Value
(I vs. II)
New Onset AF
(n ¼ 369)
History of
Hypertension 6,120 (62.3) 1,190 (72.3)* 2,848 (75.5)* 0.013 241 (65.3)
Diabetes 3,108 (31.6) 532 (32.3) 1,160 (30.8) 0.251 97 (26.3)†
Myocardial infarction 4,469 (45.5) 809 (49.2)† 1,130 (30.0)* <0.001 184 (49.9)
Heart failure hospitalization 5,767 (58.7) 1,090 (66.3)* 2,480 (65.8)* 0.732 217 (58.8)
Stroke 635 (6.5) 180 (10.9)* 388 (10.3)* 0.473 20 (5.4)
COPD 1,050 (10.7) 265 (16.1)* 525 (13.9)* 0.036 43 (11.7)
Cancer 366 (3.7) 96 (5.8)* 190 (5.0)† 0.228 19 (5.1)
Renal disease 1,032 (10.5) 359 (21.8)* 651 (17.3)* <0.001 49 (13.3)
Medications at baseline
Beta-blocker 9,094 (92.5) 1,508 (91.7) 3,484 (92.4) 0.349 350 (94.9)
Aldosterone antagonist 4,597 (46.8) 768 (46.7) 1,825 (48.4) 0.244 159 (43.1)
Diuretic 7,642 (77.8) 1,319 (80.2)† 3,228 (85.6)* <0.001 291 (78.9)
Digoxin 2,337 (23.8) 472 (28.7)* 1,916 (50.8)* <0.001 88 (23.8)
Amiodarone 693 (7.1) 410 (24.9)* 328 (8.7)† <0.001 19 (5.1)
Statins 5,623 (57.2) 997 (60.6)† 1,683 (44.6)* <0.001 213 (57.7)
Anticoagulative therapy 1,172 (11.9) 874 (53.1)* 2,685 (71.2)* <0.001 59 (16.0)†
Aspirin 6,032 (61.4) 769 (46.7)* 1,066 (28.3)* <0.001 230 (62.3)
Other antiplatelet 1,689 (17.2) 192 (11.7)* 226 (6.0)* <0.001 45 (12.2)†
Any antiplatelet 6,491 (66.0) 836 (50.8)* 1,185 (31.4)* <0.001 250 (67.8)
ICD 1,132 (11.5) 324 (19.7)* 339 (9.0)* <0.001 64 (17.3)†
CRT 546 (5.6) 200 (12.2)* 207 (5.5) <0.001 26 (7.0)
NT-proBNP, pg/ml 1,244 (694–2,521) 1,474 (774–2,876)* 1,801 (1,096–3,200)* <0.001 1,694 (819–3,154)*
KCCQ clinical summary score‡ 82.3 (65.6–92.7) 77.1 (60.4–89.6)* 74.0 (56.3–87.5)* 79.2 (63.5–91.7)*
CHA2DS2-VASc 3.5  1.7 4.1  1.8* 3.9  1.8* 0.005 3.6  1.8
CHA2DS2-VASc score $2 8,816 (89.7) 1,561 (94.9)* 3,507 (93.0)* 0.01 331 (89.7)
Values are mean  SD, n (%), or median (interquartile range). A total of 66 patients had unspeciﬁed type of atrial ﬁbrillation (AF) and an additional 106 had a history of atrial
ﬂutter or atrial ﬂutter on their electrocardiogram at randomization and are not included in the table. Patients with new onset AF were compared with patients with no AF at
randomization and during follow-up (n ¼ 9,459). *p < 0.001 for comparison with no AF. †p < 0.05 for comparison with no AF. ‡Missing in 1,862 patients.
BMI ¼ body mass index; CHA2DS2-VASc ¼ congestive heart failure, hypertension, age $75 years; diabetes mellitus, prior stroke or transient ischemic attack or thrombo-
embolism, vascular disease, age 65–74 years, sex category; COPD ¼ chronic obstructive pulmonary disease; CRT ¼ cardiac resynchronization therapy; eGFR ¼ estimated
glomerular ﬁltration rate; HF ¼ heart failure; ICD ¼ implantable cardioverter-deﬁbrillator; KCCQ ¼ Kansas City Cardiomyopathy Questionnaire; NT-proBNP ¼ N-terminal pro–B-
type natriuretic peptide; NYHA ¼ New York Heart Association.
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2495associated with a higher risk of stroke but persistent
or permanent AF was not; however, approximately
three-quarters of patients with persistent AF were
treated with an oral anticoagulant, whereas only
around one-half of patients with paroxysmal AF were.
Last, new onset (incident) AF conferred the greatest
risk of all, being associated with a higher risk both of
hospitalization and death, as well as of stroke.
Prior studies have reported conﬂicting ﬁndings as
to whether AF is an independent predictor of adverse
outcomes (3–5,12–19). This conﬂict has been thought
to reﬂect the varying level of adjustment for other
prognostic variables as patients with AF have gener-
ally been older, had more severe HF, and more co-
morbidity than did those without AF. This has led to
debate about whether AF is just a marker of more
advanced disease in sicker patients, rather than an
independent prognostic risk factor. When weexamined all patients with a history of AF we found a
similar picture to that described previously, although
LVEF was slightly higher in patients with AF
compared to those without. However, when we
compared patients with paroxysmal AF to those with
persistent or permanent AF, important differences
emerged. Patients with paroxysmal AF generally had
less evidence of advanced HF and less comorbidity,
with a risk proﬁle intermediate between individuals
without AF and those with persistent or permanent
AF (although patients with paroxysmal AF had the
highest prevalence of coronary artery disease of all
groups examined). Despite this, patients with parox-
ysmal AF exhibited a higher crude and adjusted rate
of HF hospitalization.
A unique aspect of the present study was the
measurement of NT-proBNP at baseline. This is
important because natriuretic peptides are the single
TABLE 2 Risk of Different Endpoints According to AF Type at Randomization
Events
Crude Rate per
100 PY (95% CI)
Unadjusted HR
(95% CI) p Value
Model 1 HR
(95% CI) p Value
Model 2 HR
(95% CI) p Value
Primary composite
No AF 2,572 11.0 (10.6–11.4) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Persistent/permanent AF 1,110 12.5 (11.7–13.2) 1.14 (1.06–1.22) <0.001 1.04 (0.97–1.13) 0.273 0.94 (0.87–1.02) 0.138
Paroxysmal AF 544 14.4 (13.2–15.6) 1.31 (1.19–1.43) <0.001 1.23 (1.11–1.35) <0.001 1.20 (1.09–1.32) <0.001
New onset AF 97 25.6 (21.0–31.3) 2.64 (2.15–3.24) <0.001 2.53 (2.06–3.10) <0.001 2.21 (1.80–2.71) <0.001
HF hospitalization
No AF 1,415 6.0 (5.7–6.4) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Persistent/permanent AF 639 7.2 (6.6–7.7) 1.19 (1.08–1.31) <0.001 1.04 (0.94–1.16) 0.411 0.94 (0.85–1.04) 0.239
Paroxysmal AF 364 9.6 (8.7–10.7) 1.59 (1.42–1.78) <0.001 1.37 (1.22–1.55) <0.001 1.34 (1.19–1.51) <0.001
New onset AF 50 13.2 (10–17.4) 2.67 (2.01–3.54) <0.001 2.42 (1.82–3.23) <0.001 2.11 (1.58–2.81) <0.001
CV death
No AF 1,665 6.6 (6.3–6.9) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Persistent/permanent AF 737 7.5 (7.0–8.1) 1.14 (1.05–1.24) 0.003 1.08 (0.98–1.19) 0.11 0.97 (0.88–1.07) 0.555
Paroxysmal AF 319 7.5 (6.7–8.4) 1.14 (1.01–1.28) 0.037 1.11 (0.98–1.26) 0.088 1.09 (0.97–1.24) 0.156
New onset AF 100 19.0 (15.6–23.1) 2.77 (2.26–3.39) <0.001 2.77 (2.26–3.41) <0.001 2.43 (1.97–2.98) <0.001
Pump failure death
No AF 353 1.4 (1.3–1.6) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Persistent/permanent AF 209 2.1 (1.9–2.5) 1.52 (1.28–1.81) <0.001 1.31 (1.09–1.59) 0.005 1.13 (0.94–1.37) 0.193
Paroxysmal AF 112 2.6 (2.2–3.2) 1.88 (1.52–2.32) <0.001 1.58 (1.27–1.97) <0.001 1.53 (1.22–1.91) <0.001
New onset AF 39 7.4 (5.4–10.1) 4.84 (3.46–6.77) <0.001 4.42 (3.15–6.20) <0.001 3.70 (2.63–5.21) <0.001
Sudden death
No AF 783 3.1 (2.9–3.3) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Persistent/permanent AF 279 2.9 (2.5–3.2) 0.92 (0.80–1.05) 0.229 0.98 (0.84–1.14) 0.797 0.89 (0.76–1.04) 0.142
Paroxysmal AF 107 2.5 (2.1–3.0) 0.81 (0.66–0.99) 0.043 0.92 (0.74–1.13) 0.405 0.90 (0.73–1.11) 0.319
New onset AF 29 5.5 (3.8–7.9) 2.05 (1.41–2.98) <0.001 2.20 (1.51–3.20) <0.001 1.95 (1.34–2.84) 0.001
All-cause mortality
No AF 1,979 7.9 (7.5–8.2) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Persistent/permanent AF 898 9.2 (8.6–9.8) 1.17 (1.08–1.26) <0.001 1.06 (0.97–1.15) 0.216 0.95 (0.87–1.04) 0.302
Paroxysmal AF 391 9.2 (8.3–10.2) 1.17 (1.05–1.31) 0.004 1.10 (0.98–1.23) 0.092 1.08 (0.96–1.21) 0.186
New onset AF 114 21.6 (18–26) 2.62 (2.17–3.18) <0.001 2.56 (2.11–3.10) <0.001 2.26 (1.86–2.74) <0.001
Stroke
No AF 278 1.1 (1.0–1.3) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Persistent/permanent AF 135 1.4 (1.2–1.7) 1.25 (1.02–1.54) 0.031 1.11 (0.88–1.40) 0.373 1.04 (0.83–1.32) 0.715
Paroxysmal AF 68 1.6 (1.3–2.1) 1.46 (1.12–1.91) 0.005 1.36 (1.03–1.79) 0.029 1.34 (1.02–1.76) 0.037
New onset AF 13 2.6 (1.5–4.4) 2.27 (1.30–3.98) 0.004 2.36 (1.34–4.16) 0.003 2.20 (1.25–3.88) 0.006
Model 1: age, sex, region, race, NYHA functional class, ejection fraction, heart rate, systolic blood pressure, eGFR, diabetes, BMI, time since HF diagnosis, history of HF hospitalization, history
of myocardial infarction, history of stroke, and randomized treatment (enalapril, sacubitril/valsartan, aliskiren, or combination). Model 2: Model 1 þ log NT-proBNP. A total of 172 patients had
AF of unspeciﬁed type or atrial ﬂutter at randomization and are not included above.
CI ¼ conﬁdence interval; CV ¼ cardiovascular; HR ¼ hazard ratio; PY ¼ person-years; other abbreviations as in Table 1.
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2496most powerful predictor of outcomes in HF, but no
prior study in patients with chronic HFrEF has been
able to adjust for natriuretic peptide concentration
when examining the prognostic impact of AF. Even
after incorporating NT-proBNP in our multivariable
risk models, paroxysmal (but not persistent or per-
manent AF) remained an independent predictor of HF
hospitalization as well as pump-failure death. We are
not aware of any robust prior analysis of the risk
associated with these 2 different types of AF in
chronic HFrEF. In 1 small study of hospitalized HF
patients in Japan, HF rehospitalization was more
common among the 28 individuals with paroxysmalAF, compared with 103 patients with chronic AF and
239 patients in sinus rhythm (20). However, these
ﬁndings were not conﬁrmed in a later similarly small
study from the same investigators (21).
Why paroxysmal (as opposed to persistent or per-
manent) AF is associated with this increased risk is
uncertain. It is possible that paroxysms of AF are a
reﬂection of HF instabilitymore generally (e.g., rises in
atrial pressure precipitating both episodes of AF and
decompensation leading to hospital admission). In
addition, or alternatively, patients with paroxysmal
AF (as opposed to persistent or permanent AF) may
receive less treatment to control the ventricular rate.
FIGURE 1 Cumulative Incidence of Outcomes According to Type of AF at Randomization
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The cumulative incidence of (A) the primary composite endpoint (cardiovascular [CV] death or heart failure [HF] hospitalization), (B) HF hospitalization,
(C) CV death, and (D) stroke accounting for death as a competing risk. The p values for comparison of the cumulative incidence functions according to type of
atrial ﬁbrillation (AF) (AF at randomization no AF, paroxysmal AF, or persistent or permanent AF) are based on Gray’s test. As illustrated, patients with
paroxysmal AF had the highest incidence of the primary endpoint, primarily driven by a higher rate of HF hospitalization. Patients with both types of AF versus
no AF had higher incidence of stroke.
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2497Although the rate of use of beta-blocker was similar,
the rate of use of digoxin in patients with paroxysmal
AF was just over one-half of that in patients with
persistent or permanent AF. Digoxin added to a beta-
blocker does provide better control of the ventricular
rate in AF (22). Although a trial comparing more to less
strict rate control in AF did not show an advantage to
the former, it really asked a different question (i.e., it
asked about modest differences in ventricular rate in
patients with persistent or permanent AF as opposed
to prophylactic treatment in patients at risk of parox-
ysms of potentially very rapid ventricular rate and
associated detrimental hemodynamic changes) (23).
Moreover, only 287 patients in that trial had HF and
most had preserved rather than reduced ejectionfraction. Likewise, in the 1 large trial in HF comparing a
strategy of rhythm control with one of rate control,
only one-third of patients (w430) had paroxysmal AF
(24). Therefore, it remains possible that prevention of
paroxysms of AF by catheter ablationmight reduce the
risk of decompensation in patients with HFrEF and the
value of this treatment is presently being evaluated in
a number of clinical trials (25).
Of note, new onset AF carried the greatest risk of
all, including a heightened risk of death. Although the
number of patients and events in this category was
relatively small, we believe that it is real and has been
reported previously (4,6,26). Again the reasons for
this are uncertain, although the same considerations
discussed in relation to paroxysmal AF may apply.
CENTRAL ILLUSTRATION Type of AF at Randomization Compared With Patients Without AF:
HRs of Outcomes
Outcome
Primary Endpoint
Permanent AF
Paroxysmal AF
New-onset AF
HF Hospitalization
Permanent AF
Paroxysmal AF
New-onset AF
CV Death
Permanent AF
Paroxysmal AF
New-onset AF
All-Cause Mortality
Permanent AF
Paroxysmal AF
New-onset AF
Stroke
Permanent AF
Paroxysmal AF
New-onset AF
0.5
Lower Higher
1.5
Hazard Ratio (Reference = No AF)
2.0 2.5 3.0
Mogensen, U.M. et al. J Am Coll Cardiol. 2017;70(20):2490–500.
Hazard ratios (HRs) of outcomes according to type of atrial ﬁbrillation (AF) using no AF as reference. HRswith 95%conﬁdence intervals were calculated
using cause-speciﬁc Cox models, adjusted for age, sex, region, race, New York Heart Association functional class, ejection fraction, heart rate, systolic
blood pressure, estimated glomerular ﬁltration rate, diabetes, body mass index, time since HF diagnosis, history of HF hospitalization, history of
myocardial infarction, history of stroke, log N-terminal pro–B-type natriuretic peptide, and randomized treatment (enalapril, sacubitril/valsartan,
aliskiren, or combination). The p values are for difference between paroxysmal and persistent or permanent AF. CV¼ cardiovascular.
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2498Our ﬁndings reinforce the value of using HF treat-
ments that also reduce the risk of new onset AF,
speciﬁcally renin-angiotensin system antagonists,
mineralocorticoid receptor antagonists, and beta-
blockers (27–29).Both new onset AF and paroxysmal AF were also
associated with an increased risk of stroke compared
with no AF and persistent or permanent AF. The
greater risk associated with new onset AF and
paroxysmal AF presumably, at least in part, reﬂects
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Among patients
with HFrEF, those with newly identiﬁed AF and paroxysmal AF,
rather than persistent or permanent AF, are at higher risk of
adverse outcomes, including hospitalization for worsening HF
and stroke, but not mortality.
TRANSLATIONAL OUTLOOK: Further studies are needed to
explore strategies to prevent adverse outcomes, including
stroke, in patients with HFrEF by identifying those most likely to
develop AF.
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2499the much lower use of oral anticoagulants in these
patients. Although low use of oral anticoagulants is
understandable in the patients with incident AF, it is
less so in patients with paroxysmal AF. The latter
patients had at least as high an average CHA2DS2-
VASc score as did individuals with persistent or per-
manent AF, and guidelines recommend use of oral
anticoagulants in both types of AF to reduce the risk
of thromboembolism (30). Although more than 90%
of patients with each type of AF had a CHA2DS2-VASc
score $2 (i.e., an indication for anticoagulation), only
71% of those with persistent or permanent AF and
53% of those with paroxysmal AF were actually
treated with an anticoagulant. This large gap between
the ideal and reality clearly demonstrates the
considerable potential beneﬁt of greater use of anti-
coagulant therapy in patients with HF and parox-
ysmal AF.
STUDY LIMITATIONS. The analyses of paroxysmal
versus persistent or permanent AF were not planned
prospectively. The trial inclusion and exclusion
criteria limit the generalizability of our ﬁndings re-
sults, for example, to patients with severe renal
impairment or HF with preserved ejection fraction.
Patient history of AF was investigator reported and it
is possible that some patients said not to have AF may
have had undiagnosed paroxysmal AF and AF type
might have been misclassiﬁed in some patients.
Similarly, serial ECG monitoring might have identi-
ﬁed more incident AF than was reported by in-
vestigators. Information on duration of AF at
randomization was not available. Finally, the number
of patients with new onset AF was relatively small,
and these patients also had relatively few events
during follow-up.CONCLUSIONS
Among HF patients with a history of AF, we found
those with paroxysmal AF were at greater risk of HF
hospitalization. Paroxysmal AF was also associated
with a greater risk of stroke than in patients with
persistent or permanent AF, underlining the impor-
tance of anticoagulant therapy in these patients. New
onset AF was associated with the greatest risk of all
and should prompt immediate consideration of anti-
coagulant therapy as well as close surveillance for
evidence of decompensation and treatment as
appropriate.
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APPENDIX For an expanded Methods section
as well as supplemental tables and ﬁgures,
please see the online version of this article.
